These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 24252703

  • 1. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A, Simurka P, Li P, Roy-Ghanta S, Vaughn D.
    Vaccine; 2014 Feb 19; 32(9):1121-9. PubMed ID: 24252703
    [Abstract] [Full Text] [Related]

  • 2. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW.
    Pediatr Infect Dis J; 2012 Aug 19; 31(8):848-58. PubMed ID: 22801094
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG, Clément F, Willekens J, Dewé W, Walravens K, Vaughn DW, Leroux-Roels G.
    Clin Vaccine Immunol; 2017 Jun 19; 24(6):. PubMed ID: 28446441
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, Gillard P, Arístegui J.
    Vaccine; 2010 Aug 16; 28(36):5837-44. PubMed ID: 20600478
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.
    Vesikari T, Richardus JH, Berglund J, Korhonen T, Flodmark CE, Lindstrand A, Silfverdal SA, Bambure V, Caplanusi A, Dieussaert I, Roy-Ghanta S, Vaughn DW.
    Pediatr Infect Dis J; 2015 Jul 16; 34(7):774-82. PubMed ID: 26069949
    [Abstract] [Full Text] [Related]

  • 13. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
    Langley JM, Frenette L, Chu L, McNeil S, Halperin S, Li P, Vaughn D.
    BMC Infect Dis; 2012 Oct 30; 12():279. PubMed ID: 23110320
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older.
    Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D.
    Hum Vaccin Immunother; 2012 Aug 30; 8(8):1119-25. PubMed ID: 22854661
    [Abstract] [Full Text] [Related]

  • 15. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.
    Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G.
    Clin Vaccine Immunol; 2011 May 30; 18(5):835-43. PubMed ID: 21450978
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.
    Vaccine; 2015 Jan 01; 33(1):174-81. PubMed ID: 25444803
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
    Ruiz-Palacios GM, Leroux-Roels G, Beran J, Devaster JM, Esen M, Launay O, McElhaney JE, van Essen GA, Benoit A, Claeys C, Dewé W, Durand C, Duval X, Falsey AR, Feldman G, Galtier F, Gervais P, Hwang SJ, McNeil S, Richardus JH, Trofa A, Oostvogels L, Influence65 study group.
    Hum Vaccin Immunother; 2016 Dec 01; 12(12):3043-3055. PubMed ID: 27690762
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A.
    Vaccine; 2015 Jun 04; 33(24):2800-7. PubMed ID: 25910919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.